Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts

TheFly reported connected January 29 that Stifel raised the terms people connected NRIX to $35 from $33 and maintained a Buy rating. The steadfast noted that 2026 volition beryllium a cardinal twelvemonth for bexobrutideg arsenic absorption progresses 2 registrational trials and provides further Phase 1 updates.

In contrast, connected the aforesaid day, Wells Fargo lowered the terms people connected Nurix Therapeutics, Inc. (NASDAQ:NRIX) to $29 from $30 and maintained an Overweight rating. The steadfast points retired that adjacent successful the lack of objective triggers successful 2026, the shares are inactive inexpensive and could summation successful the 2nd fractional of the twelvemonth earlier important catalysts successful 2027.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is simply a biopharmaceutical institution that develops targeted macromolecule modulation therapies utilizing its proprietary DELigase platform. NRIX focuses connected ubiquitin signaling pathways successful bid to make degraders and small-molecule programs for immunology and oncology illnesses and develops precision medicines to code unmet aesculapian needs and heighten diligent outcomes.

While we admit the imaginable of NRIX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.